Bill Wilson, MD: A Generic GLP-1 Is Needed to Prevent Patients from Turning to Unsafe Alternatives
Transcript excerpt of a conversation between Bill Wilson and Dr. Ron Najafi discussing the lack of generic alternatives for certain patent-protected drugs (implicitly GLP-1s), the role of compounding pharmacies, and affordability/insurance coverage. Wilson argues generics or correct pricing would prevent reliance on compounded products and that manufacturers (e.g., Lilly) should supply these drugs at more affordable prices.
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet